Meeting
2019 ASCO Annual Meeting
Clinical characteristics of patients with no evidence of disease (NED) versus residual disease (RES) to anti-HER2 therapy in metastatic breast cancer (MBC): A multi-institutional analysis.
Authors
Zachary William Neil Veitch
Princess Margaret Cancer Centre, Toronto, ON, Canada
Zachary William Neil Veitch , Philippe L. Bedard , Patricia A. Tang , Jessica L. Conway , Domen Ribnikar , Hamzeh Albaba , Karen M. King , Sasha M. Lupichuk , David W. Cescon
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
HER2-Positive
Citation
J Clin Oncol 37, 2019 (suppl; abstr 1034)
DOI
10.1200/JCO.2019.37.15_suppl.1034
Abstract #
1034
Poster Bd #
115
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Long-term follow up (FU) of patients with durable complete response (DCR) after chemotherapy (CT) and HER2-targeting systemic therapy (HER2-Tx) for HER2+ metastatic breast cancer (MBC).
First Author: Giuseppe Gullo
Poster
2012 ASCO Annual Meeting
Long-term follow-up (FU) of patients with durable complete response (DCR) after chemotherapy (CT) and trastuzumab (T) for HER2-altered (HER2+) metastatic breast cancer (MBC).
First Author: Giuseppe Gullo
Poster
2022 ASCO Annual Meeting
Survival of elderly patients with HER2+/HR- metastatic breast cancer in clinical practice: SEER-Medicare data 2012-2016.
First Author: Zhonghui Ou
Poster
2021 ASCO Annual Meeting
The prognostic performance of PREDICT+ in patients (pts) with HER2-positive (HER2+) early-stage breast cancer (EBC).
First Author: Elisa Agostinetto